NCT05425472: A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer |
|
|
| Recruiting | 2 | 30 | RoW | HR070803 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Esophageal Cancer | 01/23 | 03/23 | | |
NCT06383078: HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer |
|
|
| Not yet recruiting | 2 | 120 | NA | HR070803, Irinotecan Liposome, Oxaliplatin, L-OHP, Tegafur, S-1, Folinic acid, LV, 5-Fluorouracil, 5-FU | The First Affiliated Hospital with Nanjing Medical University | Efficacy and Safety | 03/27 | 12/27 | | |
